# Ringene Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ringene-biopharma

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (Sep 2, 2020)
- Investors on record: 2

## About

Established in 2017 and based in Shanghai, China, Ringene Biopharma is a biotechnology company that engaged in research and development of innovative anti-tumor drugs. The core team members have experience in drug discovery, tumor biology, project management and operations. In August 2018, the company closed an angel funding. In September 2020, new investor SDIC Venture Capital and Shenzhen Capital Group co-led series A funding for Ringene Biopharma.

Ringene Biopharma focuses on providing a variety of single-agent or combination drug solutions for drug-resistant patients with tumors. Based on a structural biology-guided drug design platform, the company focuses on key signaling proteins of RTK-MAPK pathway resistance and has established a pipeline of preclinical drug candidates for research and development.

Ringene Biopharma will use the series A funding to enhance the construction of preclinical new drug development and translational medicine platforms, accelerate the preclinical development and IND filing of drugs, and the development of small molecule new drugs in the RTK-MAPK pathway.

## Funding rounds

- Series A, Sep 2, 2020 — SDIC Venture Capital, Shenzhen Capital Real Estate Fund

## Investors

- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A